How these molecules work at the receptor level — GIP, GLP-1, and glucagon agonism, the single → dual → triple-agonist progression, and the pharmacokinetics that drive dosing. Educational reference only; nothing here is medical advice.
In 2018, the SELECT investigators enrolled the first of what would become 17,604 participants — none diabetic, all obese or overweight, every one carrying a history of established cardiovascular…
A 54-year-old woman with a BMI of 38 kg/m² and hypertension has cycled through two GLP-1 receptor agonists over four years, reaching a maximum of 11% body weight reduction before plateauing on…
Why Nausea on a GLP-1 Drug Is Not Random — It Is Pharmacologically Predictable A patient initiates semaglutide (Ozempic) at 0.25 mg/week. By day ten, meals trigger nausea intense enough to alter…
A patient arrives at an obesity medicine consultation after 24 weeks on semaglutide (Wegovy) 2.4 mg weekly with a 6.2% body weight reduction — statistically real, clinically insufficient for a…
A patient initiates semaglutide (Ozempic) at 0.25 mg/week and reports nausea beginning on day 3 of the first injection. By week 4 at the same dose, the nausea has largely resolved. By week 12…
How retatrutide's triple-receptor mechanism (GIP, GLP-1, and glucagon) is studied for weight regulation, with trial-reported figures attributed to published sources. Investigational; not FDA-approved.